Human conjunctivitis. II. Treatment.
One hundred forty-three patients (207 eyes) with conjunctivitis or blepharoconjunctivitis were investigated to determine (1) the safety of topical corticosteroid therapy and the relative efficacy of formulations of increasing potency and (2) the effectiveness of a steroid-antibiotic preparation compared to each of its components alone and to a placebo. The corticosteroids were equally effective in suppressing conjunctival inflammation; all were more effective than the placebo. Active conjunctivitis was controlled more readily by those preparations containing a steroid, both alone and in combination. The corticosteroid alone (dexamethasone) was more effective in producing inactivation of conjunctivitis than the antibiotic alone ( a mixture of neomycin sulfate and polymyxin B sulfate). This observation remained unchanged when cases of Staphylococcus aureus conjunctivitis were analyzed separately. No serious complications resulted from any treatment regimen.
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001762:Blepharitis / Q000188:drug therapy* / Q000209:etiology; D003231:Conjunctivitis / Q000188:drug therapy* / Q000209:etiology; D003907:Dexamethasone / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005141:Eyelid Diseases / Q000188:drug therapy*; D006801:Humans; D006854:Hydrocortisone; D009355:Neomycin / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D011239:Prednisolone; D013203:Staphylococcal Infections / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D011113:Polymyxins; D003907:Dexamethasone; D011239:Prednisolone; D009355:Neomycin; D006854:Hydrocortisone